GlassScriptPhysician profile
Ronnie L Bond
NPI 1639327893
$3,835.84
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $1,284 · 2021: $1,212 · 2022: $24.27 · 2023: $64.66 · 2024: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $164 · Food and Beverage: $47.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $163.51 |
| Food and Beverage | $47.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $383.19 | 2019-2023 | |
| Genzyme Corporation | $318.02 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $298.37 | 2019-2024 | Ultomiris |
| Eisai INC. | $252.80 | 2019-2021 | |
| Amgen INC. | $252.58 | 2019-2021 | |
| Emd Serono, INC. | $231.05 | 2019-2021 | |
| Ucb, INC. | $197.63 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $178.04 | 2019-2021 | |
| Acorda Therapeutics, INC | $160.19 | 2019-2020 | |
| Mdd US Operations, LLC | $152.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $152.07 | 2020-2021 | |
| Biogen, INC. | $127.54 | 2021 | |
| Greenwich Biosciences, INC. | $117.80 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $108.17 | 2019-2020 | |
| Genentech USA, INC. | $97.50 | 2020-2024 | Ocrevus, Ocrevus Zunovo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $92.66 | 2019-2020 | |
| Celgene Corporation | $71.41 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $68.11 | 2021 | |
| Csl Behring | $66.72 | 2019-2020 | |
| Lilly USA, LLC | $58.31 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $53.85 | 2020-2021 | |
| Kyowa Kirin, INC. | $48.52 | 2019-2021 | |
| Neurelis, INC. | $45.44 | 2020-2021 | |
| Promius Pharma LLC | $35.44 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $31.66 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $28.38 | 2020 | |
| Sunovion Pharmaceuticals INC. | $27.62 | 2021 | |
| Adamas Pharmaceuticals, INC. | $23.79 | 2021 | |
| Grifols USA, LLC | $22.65 | 2019 | |
| Mallinckrodt Enterprises LLC | $21.87 | 2019 | |
| Livanova USA, INC. | $17.26 | 2019 | |
| Zyla Life Sciences, INC. | $16.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.86 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.46 | 2019 | |
| Portola Pharmaceuticals, LLC | $12.82 | 2020 | |
| Abbvie INC. | $12.33 | 2021 | |
| Bausch Health US, LLC | $12.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronnie Bond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.